What question did this study set out to answer?

To evaluate the association between AGTR1 rs5186 polymorphism and cardiovascular disease risk in a Mexican population using inflammatory and metabolic biomarkers.

June 25, 2026Open Access

AGTR1 rs5186 polymorphism and inflammatory biomarkers are associated with cardiovascular disease risk in an admixed Mexican population

Q: What is the clinical evidence from this study?

Study design: Case-Control. Population: Cardiovascular disease (n=356). Intervention: AGTR1 rs5186 (A1166C) polymorphism vs. Healthy controls / Non-carriers. Primary outcome: Cardiovascular disease risk (OR 3.42, 95% CI 1.16-10.08, p=0.04).

JHJosé Francisco Herrera-MorenoUniversidad Autónoma de Nayarit NPN. Ponce-RuízUniversidad Autónoma de Nayarit ARAurora Elizabeth Rojas‐GarcíaUniversidad Autónoma de Nayarit

Key Result

The AGTR1 A1166C genotype was independently associated with a significantly increased risk of cardiovascular disease (OR 3.42) in an admixed Mexican population.

Key Points

To evaluate the association between AGTR1 rs5186 polymorphism and cardiovascular disease risk in a Mexican population using inflammatory and metabolic biomarkers.
Conducted a case-control study with 356 participants from Nayarit, Mexico
Participants categorized into three groups: CVD, hypertension free of CVD, and healthy controls
Genotyping performed via real-time PCR and adjusted analysis using logistic regression.
A1166C genotype associated with CVD risk (OR = 3.42, 95% CI: 1.16, 10.08)
Elevated SAA levels linked to CVD risk (OR = 1.01, 95% CI: 1.01, 1.02)
Increased homocysteine associated with CVD risk (OR = 3.20, 95% CI: 1.93, 5.33)

Study Design

Type

Case-Control (n=356)

Structured PICO

Population

356 participants from Nayarit, Mexico, comprising 118 with cardiovascular disease, 119 with hypertension, and 119 healthy controls.

Outcome

Association of AGTR1 rs5186 (A1166C) polymorphism with cardiovascular disease risksurrogate

The AGTR1 rs5186 polymorphism (A1166C genotype) and elevated levels of serum amyloid A and homocysteine are independently associated with increased cardiovascular disease risk in an admixed Mexican population.

Main Result

Odds Ratio: 3.42 (95% CI 1.16–10.08)

p-value: p=0.04

Limitations

No a priori power calculation for the genetic association analysis
Modest sample size limiting generalizability
Heterogeneous cardiovascular phenotypes in the CVD group
Absence of ancestry-informative markers or population stratification analyses
Case-control design precludes causal inference
Lack of evaluation of additional RAS-related polymorphisms

Abstract

Abstract The angiotensin II type 1 receptor ( AGTR1 ) rs5186 (A1166C) polymorphism has been associated with cardiovascular disease (CVD) risk. However, its relevance in genetically admixed populations, such as Mexicans, remains unclear. The aim of this study was to evaluate the association between the AGTR1 rs5186 polymorphism and CVD risk in a Mexican population, while integrating key inflammatory and metabolic biomarkers. A case-control study was conducted with 356 participants from Nayarit, Mexico, classified into three groups: CVD (n = 118), hypertension free of CVD (HTN, n = 119), and healthy controls (n = 119). Genotyping of rs5186 was performed via real-time PCR. Logistic regression models were adjusted for sociodemographic, clinical, and lifestyle variables, including serum amyloid A (SAA) and homocysteine levels. The A1166C genotype was independently associated with CVD risk (OR = 3.42, 95% CI: 1.16, 10.08). Elevated SAA (OR = 1.01, 95% CI: 1.01, 1.02) and homocysteine (OR = 3.20, 95% CI: 1.93, 5.33) were also significant predictors. These associations persisted after adjusting for potential confounders. This study highlights the relevance of AGTR1 rs5186 and inflammatory biomarkers in CVD susceptibility in a Mexican admixed population. Findings support the inclusion of genetic screening and inflammatory profiling in population-specific preventive strategies.

AIに質問

Bookmark

View Full Paper

Cite This Study

Herrera-Moreno et al. (Wed,) conducted a case-control in Cardiovascular disease (n=356). AGTR1 rs5186 (A1166C) polymorphism vs. Healthy controls / Non-carriers was evaluated on Cardiovascular disease risk (OR 3.42, 95% CI 1.16-10.08, p=0.04). The AGTR1 A1166C genotype was independently associated with a significantly increased risk of cardiovascular disease (OR 3.42) in an admixed Mexican population.

synapsesocial.com/papers/6a3d91bf408ebb922448b19c https://doi.org/https://doi.org/10.1038/s41598-026-58713-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper